Ishita Drugs & Industries Reports Mixed Q2 Results, Progresses on Facility Upgrade

1 min read Updated on 11 Nov 2025, 09:29 PM

Reviewed by

Naman SScanX News Team

Overview

Ishita Drugs & Industries Limited reported Q2 FY2026 revenue of Rs. 806.81 lakhs, up from Rs. 692.92 lakhs in Q1. However, net profit declined to Rs. 14.33 lakhs from Rs. 30.23 lakhs. The company is upgrading its manufacturing facility to comply with Revised Schedule M regulations, with Rs. 50 lakhs spent on civil construction. The project faced delays due to extended monsoon. The company maintains a strong liquidity position with Rs. 472.68 lakhs in cash and bank balances.

*this image is generated using AI for illustrative purposes only.

Ishita Drugs & Industries Limited has released its unaudited financial results for the quarter and half-year ended September 30, 2025, revealing a mixed performance amidst ongoing facility upgrades.

Financial Performance

The company reported revenue from operations of Rs. 806.81 lakhs for the quarter, contributing to a half-yearly revenue of Rs. 1499.73 lakhs. However, the net profit for the quarter saw a decline, coming in at Rs. 14.33 lakhs compared to Rs. 30.23 lakhs in the previous quarter.

Financial Metric	Q2 FY2026 (Rs. in lakhs)	Q1 FY2026 (Rs. in lakhs)
Revenue	806.81	692.92
Net Profit	14.33	30.23

The basic earnings per share (EPS) from continuing operations stood at Rs. 0.48 for the quarter.

Manufacturing Facility Upgrade

Ishita Drugs & Industries is currently undertaking a significant manufacturing facility upgradation project to comply with the Revised Schedule M regulations. The company's Board of Directors discussed the progress of this project during their meeting. Key points include:

Appointment of a civil contractor and commencement of construction.
Progress affected by higher-than-normal rainfall and an extended monsoon period.
Expenditure of nearly Rs. 50 lakhs incurred towards civil construction of the project.

Balance Sheet Highlights

As of September 30, 2025, the company's financial position shows:

Metric	Amount (Rs. in lakhs)
Total Assets	1457.37
Total Equity	1123.53
Current Assets	1326.25
Current Liabilities	326.38

Cash Flow and Liquidity

The cash flow statement reveals:

Net cash generated from operating activities: Rs. 412.24 lakhs
Net cash used in investing activities: Rs. 245.67 lakhs
Net cash used in financing activities: Rs. 177.27 lakhs

This resulted in a net decrease of Rs. 10.70 lakhs in cash and cash equivalents for the half-year period.

The company maintains a strong liquidity position with cash and cash equivalents of Rs. 46.14 lakhs and bank balances of Rs. 426.54 lakhs as of September 30, 2025.

Ishita Drugs & Industries Limited continues to navigate through challenging market conditions while investing in its future growth through facility upgrades. The impact of these investments on the company's financial performance and market position remains to be seen in the coming quarters.

Historical Stock Returns for Ishita Drugs & Indus